TD Asset Management Inc Has $75.92 Million Stake in Halozyme Therapeutics, Inc. $HALO

TD Asset Management Inc lowered its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 5.1% during the third quarter, Holdings Channel.com reports. The institutional investor owned 1,035,170 shares of the biopharmaceutical company’s stock after selling 55,590 shares during the quarter. TD Asset Management Inc’s holdings in Halozyme Therapeutics were worth $75,919,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Campbell Newman Asset Management Inc. boosted its stake in Halozyme Therapeutics by 0.4% during the 3rd quarter. Campbell Newman Asset Management Inc. now owns 36,878 shares of the biopharmaceutical company’s stock worth $2,705,000 after acquiring an additional 153 shares during the last quarter. Alps Advisors Inc. increased its stake in Halozyme Therapeutics by 3.0% in the third quarter. Alps Advisors Inc. now owns 5,926 shares of the biopharmaceutical company’s stock valued at $435,000 after purchasing an additional 170 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 174 shares during the period. Richardson Financial Services Inc. boosted its position in shares of Halozyme Therapeutics by 87.6% during the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 198 shares in the last quarter. Finally, Brown Advisory Inc. grew its holdings in shares of Halozyme Therapeutics by 0.6% in the 2nd quarter. Brown Advisory Inc. now owns 35,057 shares of the biopharmaceutical company’s stock valued at $1,824,000 after buying an additional 224 shares during the period. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $69.22 on Friday. The company has a debt-to-equity ratio of 43.89, a current ratio of 4.66 and a quick ratio of 3.66. The firm has a market cap of $8.17 billion, a price-to-earnings ratio of 27.80, a price-to-earnings-growth ratio of 0.28 and a beta of 0.97. The stock’s 50-day moving average is $72.58 and its 200-day moving average is $70.59. Halozyme Therapeutics, Inc. has a one year low of $47.50 and a one year high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The firm had revenue of $451.77 million for the quarter, compared to the consensus estimate of $446.13 million. During the same quarter in the previous year, the business posted $1.26 earnings per share. The firm’s quarterly revenue was up 51.6% compared to the same quarter last year. Equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Wall Street Zen cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. Wells Fargo & Company increased their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. Citizens Jmp raised their price target on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 4th. TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Finally, HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. Six equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $78.56.

Insider Activity at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the completion of the transaction, the director owned 40,123 shares in the company, valued at approximately $2,818,640.75. This represents a 4.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total transaction of $1,522,400.00. Following the completion of the transaction, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at approximately $53,947,690.28. This trade represents a 2.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 49,398 shares of company stock valued at $3,650,592 over the last ninety days. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.